Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $17 and keeps an Equal Weight rating on the shares. With Gr4 liver enzyme AE developing into a Gr5 event, the firm thinks there could be increased uncertainty in the nex-z program. Wells awaits clarity on potential cause to assess full implication as well as potential requirements for resuming studies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMP
- Intellia Therapeutics price target lowered to $14 from $24 at Barclays
- Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty
- Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback